Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. JYNT
JYNT logo

JYNT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Joint Corp (JYNT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
8.950
1 Day change
-1.10%
52 Week Range
13.000
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

JYNT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading near a flat to slightly weak level, technical momentum is mixed, options sentiment is bearish, and there is no strong proprietary buy signal. The best call is to wait rather than buy immediately.

Technical Analysis

Price closed at 8.94, just below the previous close of 8.97 (-0.11%). The MACD histogram is negative at -0.0283 and still below zero, which suggests momentum is weak, though the contraction shows downside pressure is not accelerating. RSI_6 at 52.533 is neutral, so there is no oversold entry signal. Moving averages are converging, indicating a choppy trend rather than a strong uptrend. Key levels to watch are pivot 8.997, resistance at 9.551 and 9.893, and support at 8.443 and 8.101. Overall, the chart shows consolidation with a slight bearish tilt, not a strong buy setup.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is bearish based on the very high open interest put-call ratio of 4.22, showing far more puts than calls outstanding. Implied volatility is extremely elevated at 202.51 with IV percentile at 100 and IV rank above 105, which signals expensive options pricing and heightened bearish or event-driven positioning. Call open interest is only 370 versus put open interest of 1,563. There was no option volume today, so there is no fresh bullish flow to offset the bearish skew.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
8

Positive Catalysts

  • ["The Joint Chiropractic opened a new clinic in Rhode Island, expanding into its 44th state.", "This supports continued network expansion and reinforces its position as the largest chiropractic network in the U.S.", "Insiders are buying, with buying amount up 24955.71% over the last month.", "Analyst and market activity is not showing major negative disruptions from hedge funds, which are neutral."]

Neutral/Negative Catalysts

  • ["No strong buy signal from Intellectia proprietary signals: AI Stock Picker has no signal and SwingMax has no signal recently.", "Options positioning is strongly bearish with a 4.22 put-call ratio.", "Technical momentum is weak with MACD below zero and only neutral RSI.", "There is no supportive financial snapshot available from the latest quarter, so there is no clear fundamental acceleration to justify an immediate long-term purchase.", "Hedge funds are neutral with no significant positive trading trend.", "No recent congress trading data or influential figure buying support is available."]

Financial Performance

No usable latest-quarter financial snapshot was provided because the financial data returned an error. That means there is no confirmable recent revenue, earnings, or margin trend to support a long-term buy decision. Based on the available information, fundamentals cannot be used as a bullish confirmation here.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no evidence of a recent upgrade cycle or rising Wall Street target trend. Wall Street’s visible posture from the available data is mixed to cautious: neutral hedge fund activity, bearish options sentiment, and no strong bullish analyst confirmation.

Wall Street analysts forecast JYNT stock price to rise
5 Analyst Rating
Wall Street analysts forecast JYNT stock price to rise
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 9.050
sliders
Low
9
Averages
11.33
High
14
Current: 9.050
sliders
Low
9
Averages
11.33
High
14
Roth Capital
Buy
downgrade
$14 -> $12
AI Analysis
2026-03-13
Reason
Roth Capital
Price Target
$14 -> $12
AI Analysis
2026-03-13
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Joint Corp. to $12 from $14 and keeps a Buy rating on the shares. The company's Q4 results exceeded estimates while its 2026 guidance largely mirrors the firm's model, the analyst tells investors in a research note. Roth adds, however, that the management's post-refranchising pro forma model is "underwhelming", even though it continues to see significant long-term upside.
B. Riley
B. Riley
Buy -> Neutral
downgrade
$18 -> $9
2025-11-07
Reason
B. Riley
B. Riley
Price Target
$18 -> $9
2025-11-07
downgrade
Buy -> Neutral
Reason
B. Riley downgraded Joint Corp. to Neutral from Buy with a price target of $9, down from $18. The company's Q3 comps were down 2.0%, reflecting continued softness in new patient acquisition, the analyst tells investors in a research note. The firm Joint's fiscal 2025 as "transitional," as the company tests initiatives and completes refranchising. It cites deteriorating trends for the downgrade.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for JYNT
Unlock Now

People Also Watch